Chronic Hepatitis C Infection Clinical Trial
Official title:
Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)
Prospective, longitudinal multi-center study performed in 15 participating substitution
centers in Germany.
Aims:
- Primary objective: To compare the impact of the different substitution drugs (methadone,
buprenorphine, and suboxone) on the neurocognitive, emotional, and quality-of-life-related
tolerability in opioid dependent patients under HCV treatment.
- Secondary objective: To investigate if IFN therapy impairs efficacy (with respect to e.g.
retention rates, concomitant drug use and in particular neurocognitive function) and
tolerability of agonist maintenance treatment with methadone, buprenorphine, or suboxone
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02219503 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
|
Phase 3 | |
| Completed |
NCT02216422 -
A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection
|
Phase 3 | |
| Completed |
NCT01700179 -
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
|
Phase 1 | |
| Completed |
NCT02486406 -
A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
|
Phase 2/Phase 3 | |
| Completed |
NCT01704755 -
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
|
Phase 3 | |
| Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
| Completed |
NCT01225380 -
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
|
Phase 2 | |
| Completed |
NCT02065999 -
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
|
||
| Completed |
NCT01716585 -
A Study to Evaluate Chronic Hepatitis C Infection
|
Phase 3 | |
| Completed |
NCT01715415 -
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
|
Phase 3 | |
| Completed |
NCT01453075 -
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
|
Phase 1 | |
| Completed |
NCT01011166 -
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
|
Phase 2 | |
| Completed |
NCT00557583 -
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
|
Phase 1 | |
| Terminated |
NCT01586325 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
|
Phase 1 | |
| Recruiting |
NCT02578693 -
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
|
||
| Recruiting |
NCT02583685 -
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
|
Phase 2 | |
| Completed |
NCT02576314 -
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
|
Phase 3 | |
| Not yet recruiting |
NCT01835938 -
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
|
Phase 1/Phase 2 | |
| Completed |
NCT01055821 -
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
|
Phase 2 | |
| Completed |
NCT01833533 -
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
|
Phase 3 |